Biocon enters R&D partnership with Bristol-Myers Squibb
Thursday, 15 March 2007, 17:30 IST
Printer Print Email Email
BANGALORE: India's biotech major Biocon's subsidiary Syngene has entered into partnership with Bristol-Myers Squibb, one of the world's leading pharmaceutical firms, to provide research and development (R&D) services for discovery and early drug development. "Bristol-Myers Squibb has been a valued customer of Syngene since 1998. This enhanced partnership with Bristol-Myers Squibb heralds a new phase in Syngene's advancing capabilities in providing high end services in discovery research," added Goutam Das, Chief Operating Officer, Syngene International. Bristol-Myers Squibb will significantly increase the scope of its existing relationship with Biocon to further develop integrated capabilities in India in medicinal chemistry, biology, drug metabolism, and pharmaceutical development. Under the terms of the agreement Biocon, through its subsidiary Syngene International, will work with Bristol-Myers Squibb to establish a research facility in Bangalore that could ultimately house more than 400 scientists to help advance Bristol-Myers Squibb’s development of new drugs. "The new research facility will mark a significant step forward in our evolution as a valuable partner to the global pharmaceutical industry," Kiran Mazumdar-Shaw, chairperson of the Biocon Group, told a media gathering here on Wednesday. Syngene provides customized R&D services to pharmaceutical and biotechnology companies on a platform of confidentiality and intellectual property protection. "This broad expansion of R&D in India will allow us to grow competitively while maintaining our industry-leading position in productivity and innovation," said Elliott Sigal, M.D., Chief Scientific Officer, and President, Pharmaceutical Research Institute, Bristol-Myers Squibb.
Source: IANS
siliconindia